SBIR/STTR Research Award

Radioactive Stents for Brachytherapy of Esophageal Cancers

Award identifier 816f390dc4cb715052ad88b793f62004b7569c05333d86ea826c428792821d92Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,551,134

Program and phase

SBIR · Phase II

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
XL Sci Tech Inc
Proposal award date
2015-05-05
Contract end date
2018-04-30
UEI
H1Z8MEH658H9
Solicitation number
PA14-071
Topic code
102

Research abstract

DESCRIPTION provided by applicant Current practice in the USA for inoperable esophageal cancer is a palliative treatment using metal stent for end stage cancer patients Outside the USA especially in far east countries including China and Korea there have been reported clinical benefits of attaching sealed sources such as prostate seeds to the outside of an esophageal stent Although simple and preliminary such radioisotope sources had doubled the mean survival period with high statistical confidence The investigators have demonstrated the feasibility of an advanced radioactive esophageal stents that will maximize dose to the tumors and significantly shorten the dose delivery time to more quickly achieve maximized clinical benefits A broader collaboration has been established among stent manufacturer surgical experts leading dosimetrist and regulatory professionals for the development of radioactive esophageal stents The ultimate goal is to improve treatment efficacy by matching radiation dose distribution to tumor distribution The specific aims include device safety demonstration of radioactive esophageal stents obtaining k FDA clearance The Phase II research will begin with in vivo biocompatibility assessment and end with preliminary clinical assessment using the proposed advanced radioactive esophageal stents PUBLIC HEALTH RELEVANCE The successful introduction of radioactive esophageal stent has the potential to dramatically improve the efficacy of esophageal cancer treatment especially for earlier stage inoperable esophageal cancers The use of proper radiation sources is expected to improve the safety and efficacy of radioactive esophageal stent This project is to establish the safety and preliminary efficacy of new radioactive esophageal stents with personalized dosimetry to fill the void in the USA for radioactive esophageal stents and to increase the USAandapos s competitiveness in esophageal cancer treatment With early detection and accurate dosimetry it is possible to transform the palliative esophageal treatment to a possible cure for inoperable esophageal cancers

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

17 SBIR/STTR records share this UEI (1995–2021). Reported award amounts total $7,991,308. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.